| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37549e0727671e86ec014524c6fc6992 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-864
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3a5e59feb58646429888bfb64e0b9b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70718daa410328f534a17285d06950f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3261c7db08deb6badfbfc02fa4af4be5 |
| publicationDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018265893-A1 |
| titleOfInvention |
Viral vectors for the treatment of diabetes |
| abstract |
They are provided gene constructs comprising a nucleotide sequence encoding the Insulin-like growth factor 1 (IGF-1) of a mammal; and target sequences of a microRNA of a tissue where the expression of IGF-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them. They are useful in the treatment and/or prevention of diabetes mellitus in mammals, wherein a dysfunction and/or a loss of the beta-cells of the islets of Langerhans is present. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021139933-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022162067-A1 |
| priorityDate |
2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |